The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel

Molecular Pharmacology

Volumn 60, Issue 1, 2001, Pages 104-113

  Gruol, Donald J ^a   Bernd, Josh ^a   Phippard, Alba E ^a   Ojima, Iwao ^b   Bernacki, Ralph J ^c  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CYCLOSPORIN; GLYCOPROTEIN P INHIBITOR; MUTANT PROTEIN; PACLITAXEL; PROTEIN INHIBITOR; PUROMYCIN; SBRA 31012; TAXANE DERIVATIVE; TRA 96023; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG INHIBITION; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TRANSPORT; FEMALE; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ANALYSIS;

EID: 0034954447     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.60.1.104     Document Type: Article

References (40)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Kinetic analysis of the mechanism of action of the multidrug transporter
3. Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region
4. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis
5. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
6. Two different regions of phosphoglycoprotein are photoaffinity labeled by azidopine
7. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
8. Multidrug-resistant human sarcoma cells with a mutant Pglycoprotein, altered phenotype, and resistance to cyclosporins
9. Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335)
10. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene
11. Deletion and insertion mutants of the multidrug transporter
12. Identification of the cyclosporin-binding site in P-glycoprotein
13. Localization of the iodomycin binding site in hamster P-glycoprotein
14. Modulatory effects on substrate specificity of independent mutations at the serine939/941 position in predicted transmembrane domain 11 of P-glycoproteins
15. Mechanism of action of P-glycoprotein in relation to passive membrane permeation
16. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
17. 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein
18. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein
19. Mutagenesis of transmembrane domain 11 of P-glycoprotein by alanine scanning
20. Differentiated functions expressed by cultured mouse lymphoma cells. II. Theta antigen, surface immunoglobulin and a receptor on cells of a thymoma cell line
21. Is the multidrug transporter a flippase?
22. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site
23. Multidrug resistance of cancer cells
24. Mutational analysis of the P-glycoprotein first intracellular loop and flanking transmembrane domains
25. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein
26. Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane
27. Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate
28. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol- modification techniques
29. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis
30. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal
31. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin
32. New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells
33. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells
34. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis
35. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer
36. New colorimetric cytotoxicity assay for anticancer-drug screening
37. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain I of human MDR1/P-glycoprotein
38. Identification of P-glycoprotein mutations causing a loss of steroid recognition and transport
39. Identification of the domains of photoincorporation of the 3′-and 7-benzophenone analogues of Taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein
40. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1